Compare VNET Group Inc (VNET) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VNET Group Inc vs Zoetis Inc — how do they compare? VNET Group Inc trades at $7.38 (market cap $2.14B), while Zoetis Inc trades at $73.49 (market cap $31.14B). The key difference: Zoetis Inc is far larger — about 14.6× VNET Group Inc's market cap, and Zoetis Inc pays a 2.81% dividend while VNET Group Inc pays none. Which is the better fit depends on your goals.
| VNET | ZTS | |
|---|---|---|
Market Cap | $2.14B | $31.14B |
Sector | Technology | Health |
52-Week High | $14.03 | $156.76 |
52-Week Low | $6.29 | $71.91 |
Enterprise Value | $5.29B | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VNET trades at $7.40, down 1.07% today, with a neutral technical signal and bearish moving averages. The company reported a net loss of $256.77 million in 2025, with negative profit margins and ROE, though revenue grew to $9.95 billion. Recent news highlights strategic investor entry and AI-driven demand boosting wholesale data center growth.
The outlook is mixed: analyst consensus is 62.5% buy with a 54% upside target, but persistent losses and high debt pose risks. Investment opportunity hinges on execution of capacity expansion and AI demand, while investors face volatility from earnings misses and competitive pressures in China's data center market.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
